Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Exact Sciences ( (EXAS) ) has issued an update.
Exact Sciences Corp. announced the signing of a new $500 million revolving credit agreement, replacing its previous credit arrangement, to enhance working capital and corporate operations. The company also reported strong preliminary financial results for the fourth quarter of 2024, with a 10% revenue increase compared to the previous year, and plans to launch three new cancer tests in 2025, which is expected to bolster its market position and advance its mission in cancer diagnostics.
More about Exact Sciences
Exact Sciences Corp. is a leading provider of cancer screening and diagnostic tests, notable for its products such as Cologuard and Oncotype DX. The company focuses on cancer prevention, early detection, and personalized treatment, aiming to empower patients and healthcare professionals with actionable insights.
YTD Price Performance: -0.75%
Average Trading Volume: 2,402,224
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $10.46B
Learn more about EXAS stock on TipRanks’ Stock Analysis page.
